Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development
Authors
Keywords
-
Journal
EXPERT OPINION ON EMERGING DRUGS
Volume 19, Issue 4, Pages 459-470
Publisher
Informa Healthcare
Online
2014-10-25
DOI
10.1517/14728214.2014.969239
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy
- (2015) Bo Cao et al. Oncotarget
- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Overdiagnosis and Overtreatment of Prostate Cancer
- (2014) Stacy Loeb et al. EUROPEAN UROLOGY
- Discovery of Small-Molecule Inhibitors Selectively Targeting the DNA-Binding Domain of the Human Androgen Receptor
- (2014) Huifang Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- Preclinical Evaluation of Imaging Biomarkers for Prostate Cancer Bone Metastasis and Response to Cabozantinib
- (2014) Timothy J. Graham et al. JNCI-Journal of the National Cancer Institute
- Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer
- (2013) William L. Dahut et al. BJU INTERNATIONAL
- Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer
- (2013) M. Dror Michaelson et al. JOURNAL OF CLINICAL ONCOLOGY
- Metabolomic Profiling Identifies Biochemical Pathways Associated with Castration-Resistant Prostate Cancer
- (2013) Akash K. Kaushik et al. JOURNAL OF PROTEOME RESEARCH
- Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial
- (2013) Ethan Basch et al. LANCET ONCOLOGY
- Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial
- (2013) John C Araujo et al. LANCET ONCOLOGY
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Pathogenesis and Progression of Prostate Cancer
- (2013) Randy Schrecengost et al. SEMINARS IN ONCOLOGY
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401
- (2012) William Kevin Kelly et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial
- (2012) David C. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- The mutational landscape of lethal castration-resistant prostate cancer
- (2012) Catherine S. Grasso et al. NATURE
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel approaches and future directions in castration-resistant prostate cancer
- (2011) C. Nabhan et al. ANNALS OF ONCOLOGY
- Dasatinib inhibits both osteoclast activation and prostate cancer PC-3 cell-induced osteoclast formation
- (2011) John C. Araujo et al. CANCER BIOLOGY & THERAPY
- Fyn Is Downstream of the HGF/MET Signaling Axis and Affects Cellular Shape and Tropism in PC3 Cells
- (2011) A. R. Jensen et al. CLINICAL CANCER RESEARCH
- Emerging novel therapies in the treatment of castrate-resistant prostate cancer
- (2011) Alym Abdulla et al. CUAJ-Canadian Urological Association Journal
- New Therapies for Castration-Resistant Prostate Cancer: Efficacy and Safety
- (2011) Himisha Beltran et al. EUROPEAN UROLOGY
- Contemporary Role of Androgen Deprivation Therapy for Prostate Cancer
- (2011) Vincenzo Pagliarulo et al. EUROPEAN UROLOGY
- Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy
- (2011) Benedetto Farsaci et al. INTERNATIONAL JOURNAL OF CANCER
- Differential transformation capacity of Src family kinases during the initiation of prostate cancer
- (2011) H. Cai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer
- (2011) Young E. Whang et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Cediranib/AZD2171 Inhibits Bone and Brain Metastasis in a Preclinical Model of Advanced Prostate Cancer
- (2010) J. J. Yin et al. CANCER RESEARCH
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- An update on androgen deprivation therapy for prostate cancer
- (2010) Nima Sharifi et al. ENDOCRINE-RELATED CANCER
- A sex-specific role for androgens in angiogenesis
- (2010) Daniel P. Sieveking et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- MET signalling: principles and functions in development, organ regeneration and cancer
- (2010) Livio Trusolino et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases
- (2010) Y Liu et al. ONCOGENE
- An Open-Label, Single-Arm Phase Two Trial of Gefitinib in Patients With Advanced or Metastatic Castration-Resistant Prostate Cancer
- (2009) Carmel Pezaro et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy
- (2009) G. Sonpavde et al. ANNALS OF ONCOLOGY
- Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer
- (2009) Jeanny B. Aragon-Ching et al. BJU INTERNATIONAL
- Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis
- (2009) T Koreckij et al. BRITISH JOURNAL OF CANCER
- PDGF-D Signaling: A Novel Target in Cancer Therapy
- (2009) Zhiwei Wang et al. CURRENT DRUG TARGETS
- Emerging therapies in castrate-resistant prostate cancer
- (2009) Kiran Lassi et al. CURRENT OPINION IN ONCOLOGY
- Critical review of prostate cancer predictive tools
- (2009) Shahrokh F Shariat et al. Future Oncology
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
- (2009) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Erlotinib Has Moderate Single-agent Activity in Chemotherapy-naïve Castration-resistant Prostate Cancer: Final Results of a Phase II Trial
- (2009) Chadi Nabhan et al. UROLOGY
- Targeting Src Family Kinases Inhibits Growth and Lymph Node Metastases of Prostate Cancer in an Orthotopic Nude Mouse Model
- (2008) S. I. Park et al. CANCER RESEARCH
- A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer
- (2008) W. L. Dahut et al. CLINICAL CANCER RESEARCH
- The ErbB kinase domain: Structural perspectives into kinase activation and inhibition
- (2008) Ron Bose et al. EXPERIMENTAL CELL RESEARCH
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started